COVID-19 (SARS-CoV-2) infection has been taking on pandemic dimensions. Preventive infection measures, as well as epidemiological, pathophysiological, diagnostic, and treatment expertise, are desperately needed for this virus. Advances in diagnostic tests, whether for antibody detection through "fast" tests or for detecting the presence of the virus (using the technique of RT-PCR of respiratory samples from affected patients), are critical because they aid in epidemiology, case tracking, and outbreak containment, as well as earlier disease diagnosis, which leads to a better outcome, especially in severe cases. Lymphocytopenia, thrombocytopenia, and increased D-dimer levels are all common haematological anomalies in COVID-19. These changes are more widespread and evident in patients with severe COVID-19 disease, suggesting that they could be used as a biomarker for those who require hospitalisation and intensive care unit care. Early in the course of COVID-19 infection, subtle haematological alterations may develop; increasing disease is associated with considerable haematological abnormalities that may guide the therapeutic plan and predict patient fate.
Title : Phlebotomy therapy in Sickle cell disease of double heterozygosity HbSC and rare congenital erythrocytosis in hemoglobin variants
Epifania Rita Testa, S Maria degli Angeli Hospital, Italy
Title : The utility of SYNTAX score predictability by electrocardiogram parameters in patients with unstable angina
Hamed Bazrafshan, Shiraz University of Medical Sciences, Iran (Islamic Republic of)
Title : Safety of not withholding Clopidogrel Therapy during the immediate several days pre and post Trans-Urethral Resection of Prostate (TURP) A retrospective cohort study
Ahmed Kamel Abdulhamid, University of Kerbala, Iraq
Title : The contested market of plasma
Jean Mercier Ythier, University of Paris-Panthéon-Assas, France